Macular Degeneration: all 1,490 studies
Page 9 of 15. Open to participants first (208), then studies with results posted, then the rest; newest registration first within each.
- Effect Aflibercept on Ocular PerfusionCompletedNCT03804099Phase 4
- Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVOTerminatedNCT03790852Phase 1
- Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular DegenerationCompletedNCT03777254Phase 1
- Stem Cells Therapy in Degenerative Diseases of the RetinaStatus unknownNCT03772938Phase 1
- Assessment of Visual Function With a Portable Brain-computer InterfaceStatus unknownNCT03760055
- Reading Analysis in Ophthalmologic PatientsStatus unknownNCT03750149Not applicable
- ADVM-022 Intravitreal Gene Therapy for Wet AMDCompletedNCT03748784Phase 1
- Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMDCompletedNCT03744806
- Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular DegenerationCompletedNCT03744767Phase 2
- Cooling Anesthesia for Intravitreal InjectionCompletedNCT03732287Phase 1/2
- JY028 Single Vitreous Injection in a Phase 1 Clinical Trial in nAMD PatientsStatus unknownNCT03725566Not applicable
- Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMDCompletedNCT03725501Phase 2
- Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.CompletedNCT03714308
- Safety and Tolerability of Oral CM082 in Patients With wAMDStatus unknownNCT03710863Phase 2
- Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular DegenerationTerminatedNCT03699618
- Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in PlaceCompletedNCT03690505Not applicable
- Non Exudative AMD Imaged With SS-OCTStatus unknownNCT03688243
- Intravitreal Anti-vascular Endothelial Growth Factor Administration and Its Influence on Vitreomacular Interface- and Retinal Morphology in Eyes With Neovascular Age-related Macular DegenerationCompletedNCT03680326
- Retinal Pigment Epithelial Characteristics in Eyes With Neovascular Age-related Macular Degeneration Following Long-term Treatment With Anti Neovascular Endothelial Growth FactorCompletedNCT03679156
- TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) SubjectsStatus unknownNCT03675880Phase 1
- Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)CompletedNCT03668054Phase 3
- Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)TerminatedNCT03630952Phase 3
- Assay of Pro-angiogenic Cytokines in Exudative Age-Related Macular DegenerationCompletedNCT03630562Not applicable
- CLN-0046: Treatment of AMD Subjects With OTX-TKICompletedNCT03630315Phase 1
- A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular DegenerationCompletedNCT03626636Phase 2
- Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical TrialStatus unknownNCT03609307Phase 2/3
- Effect of Vitrectomy on the Evolution of Refractory Diabetic Macular EdemaWithdrawnNCT03603990Not applicable
- Intense Treatment Regimen With Intravitreal Aflibercept InjectionStatus unknownNCT03594461Phase 1/2
- AAVCAGsCD59 for the Treatment of Wet AMDCompletedNCT03585556Phase 1
- Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)TerminatedNCT03577899Phase 3
- Shanghai Beixinjing Diabetic Eyes StudyStatus unknownNCT03571217
- Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal InjectionsStatus unknownNCT03571100Early Phase 1
- Single or Combined Protocols for NV-AMDCompletedNCT03552770Phase 4
- Amniotic Membrane for Recurrent Macular HoleStatus unknownNCT03528122Not applicable
- An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational StudiesCompletedNCT03521895
- Blood Coagulation Parameters in Patients Receiving Intravitreal Aflibercept for Age-related Macular DegenerationCompletedNCT03509623Not applicable
- Comparison of Complement Factors and Genetic Polymorphisms of AMD Between Patients With Systemic Lupus Erythematosus (SLE) With and Without Retinal "Pseudo-drusen-like" Deposits: Case-control Study (PL-AMD)CompletedNCT03504540
- The Association of the Peripheral Retinal Changes and Genotypic Changes in Patients With Age Related Macular DegenerationCompletedNCT03492853
- Study of PAN-90806 Eye Drops, Suspension for Neovascular AMDCompletedNCT03479372Phase 1/2
- Research of Automated Maculopathy Screening Based on AI Techniques Using OCT ImagesStatus unknownNCT03476291
- A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin AmericaCompletedNCT03470103
- Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly AfliberceptStatus unknownNCT03468296Phase 4
- Carbidopa-Levodopa in Dry AMD With Geographic AtrophyTerminatedNCT03451500Phase 2
- Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)WithdrawnNCT03446144Phase 2
- Correlation Between Visual Acuity Measurements, Quality of Life and Morphological Parameters in Wet AMD PatientsCompletedNCT03438669
- Wenzhou Dry Age-related Macular Degeneration (AMD) Progression StudyStatus unknownNCT03433885
- Ziv-aflibercept Efficacy in Better Regulating AMDCompletedNCT03423823Phase 2
- Comparison of Cytokine Profiles in Aqueous Humor of Patients With Age Related Macular Degeneration (AMD)CompletedNCT03418220Not applicable
- Prevalence of Age Related Macular Degeneration (ARMD) in Parkinson's Patients and Assesment of the Role of L-DOPACompletedNCT03415984
- Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)CompletedNCT03411941
- SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to MyopiaCompletedNCT03409250Phase 4
- Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMDCompletedNCT03393767Phase 4
- PRIMA US-Feasibility Study in Atrophic Dry AMDCompletedNCT03392324Not applicable
- A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular DegenerationCompletedNCT03387566Phase 1
- Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration PatientsCompletedNCT03382587
- Retinal Imaging Using NOTAL-OCTCompletedNCT03374020
- Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular DegenerationCompletedNCT03372746
- Development of Novel Clinical Endpoints in Intermediate AMDActive, not recruitingNCT03349801
- A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMDCompletedNCT03345082Phase 2
- Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMDCompletedNCT03335852Phase 1
- Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular DegenerationCompletedNCT03333954Not applicable
- The Potential Role of Dietary Antioxidant Capacity on Age-Related Macular DegenerationCompletedNCT03326401
- Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in TaiwanCompletedNCT03324542
- Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular DegenerationCompletedNCT03313401
- Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMDCompletedNCT03312283Phase 1
- The Safety and Tolerability of Sub-retinal Transplantation of SCNT-hES-RPE Cells in Patients With Advanced Dry AMDStatus unknownNCT03305029Phase 1
- Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt DiseaseCompletedNCT03297515Not applicable
- Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)CompletedNCT03295877Phase 1
- Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical PracticeCompletedNCT03290794
- Village-Integrated Eye Worker Trial II - PilotCompletedNCT03278587Not applicable
- The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical SettingCompletedNCT03278262
- Visual Function Tests in Age-related Macular DegenerationTerminatedNCT03275753
- A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular DegenerationCompletedNCT03249740Phase 1
- Evaluate the Quality of Life of Patients With AMDCompletedNCT03242083
- Dark Adaptation in Participants With Age-Related Macular DegenerationCompletedNCT03225131
- Pars Plana Vitrecromy in Patients Aged 85 Years and AboveCompletedNCT03222362
- Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)CompletedNCT03216538Phase 1/2
- The Evolution of Visual Acuity Measured by Electronic Tablet / Computer of Exudative AMD PatientsStatus unknownNCT03214484Not applicable
- Cataract and AMD in a Trial of a Multivitamin and Cocoa ExtractStatus unknownNCT03205202Phase 4
- Surgical Management of Optic Disc Pit MaculaopathyCompletedNCT03185936Not applicable
- Intravitreal Aflibercept for Submacular HemorrhageCompletedNCT03169660Phase 4
- Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a SimulatorCompletedNCT03166202
- Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59CompletedNCT03144999Phase 1
- Deficits, Adaptation and Cerebral Functional Reorganization of Visual Retinotopic Treatments During Normal and Pathological Aging (Age-related Macular Degeneration and Glaucoma)TerminatedNCT03133117Not applicable
- Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular DiseasesStatus unknownNCT03128463
- Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral ImagingTerminatedNCT03105609
- Automatic Self Transcending Meditation (ASTM) for Patients With Severe Age Related Macular Degeneration (AMD)Status unknownNCT03104608Not applicable
- Retinal Pigment Epithelium Safety Study for Patients in B4711001Active, not recruitingNCT03102138
- AMD Ryan Initiative Study (ARIS)CompletedNCT03092492
- Flicker Fusion Thresholds Between Young and Old Subjects at Various Luminance LevelsCompletedNCT03079570
- Smartphone Screening for Eye DiseasesCompletedNCT03076697
- Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGFCompletedNCT03071055Phase 2
- Timing of Low Vision Rehabilitation in Anti- Vascular Endothelial Growth Factor (VEGF) TherapyCompletedNCT03065907Not applicable
- Implantation of Add on Lens for Age Related Macular Degeneration Patients With Low VisionStatus unknownNCT03061682Not applicable
- Cytokine and Visual Outcome Variations in Eyes Receiving RanibizumabStatus unknownNCT03056092Phase 4
- Cytokine and Visual Outcome Variations in Eyes Receiving AfliberceptStatus unknownNCT03056079Phase 4
- Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word（STONE）Status unknownNCT03054818
- Use of Self-management Group to Improve Quality of Life in Patients With Low VisionWithdrawnNCT03046485Not applicable
- Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem CellsStatus unknownNCT03046407Phase 1/2
- 30g vs 33g Needle for Intravitreal InjectionsCompletedNCT03038048Not applicable